Sphingolipids and membrane targets for therapeutics
Current Opinion in Chemical Biology, ISSN: 1367-5931, Vol: 50, Page: 19-28
2019
- 20Citations
- 42Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations20
- Citation Indexes20
- 20
- CrossRef15
- Captures42
- Readers42
- 42
Review Description
Lipids and membranes are often strongly altered in various diseases and pathologies, but are not often targeted for therapeutic advantage. In particular, the sphingolipids are particularly sensitive to altered physiology and have been implicated as important players in not only several rare hereditary diseases, but also other major pathologies, including cancer. This review discusses some potential targets in the sphingolipid pathway and describes how the initial drug compounds have been evolved to create potentially improved therapeutics. This reveals how lipids and their interactions with proteins can be used for therapeutic advantage. We also discuss the possibility that modification of the physical properties of membranes could also affect intracellular signaling and be of therapeutic interest.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1367593118302035; http://dx.doi.org/10.1016/j.cbpa.2019.02.015; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85062961319&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/30897494; https://linkinghub.elsevier.com/retrieve/pii/S1367593118302035; https://dx.doi.org/10.1016/j.cbpa.2019.02.015
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know